文献速递结核与非结核分枝杆菌

儿童结核一线治疗不良事件:系统综述与Meta分析

Adverse Events of First-Line Therapy for Pediatric Tuberculosis: A Systematic Review and Meta-Analysis.
PubMed 文献 · Clin Infect Dis · 2026-01-01

该系统综述与Meta分析纳入40项研究共5021例≤19岁结核病患儿,682例(13.6%)发生712例次不良事件,60例(1.2%)因不良事件改变治疗。WHO 2010高剂量方案的不良事件比例显著高于2010年前剂量方案,肝毒性总体无显著差异但部分亚组显著增加。

要点

  • 儿童结核一线治疗中13.6%发生不良事件,1.2%因不良事件改变治疗。
  • WHO 2010高剂量方案不良事件比例26% vs 2010年前剂量8%,严重不良事件比例亦更高。
  • 肝毒性总体无显著差异,但2010剂量后部分亚组肝毒性显著增加。

核心结论

  • 儿童高剂量方案与不良事件增加相关,提示应谨慎对待进一步增加剂量,并需额外研究治疗耐受性。
  • 研究结论受观察性试验发表偏倚的限制。

研究设计与样本

  • 系统综述与Meta分析,检索MEDLINE、Embase、Scopus、Cochrane CENTRAL、WHO Global Index Medicus和ClinicalTrials.gov。
  • 纳入报告≤19岁结核病患儿接受一线药物治疗不良事件的研究,共40项研究、5021例参与者。
  • 采用比例Meta分析生成不良事件的合并比例,方案在PROSPERO注册。

主要发现

  • 682例(13.6%)参与者发生712例次不良事件;60例(1.2%)因不良事件改变治疗。
  • WHO 2010剂量方案发生任何不良事件的儿童比例显著高于2010年前剂量方案:26%(95%CI 18%-34%)vs 8%(95%CI 4%-15%)。
  • WHO 2010剂量方案发生严重不良事件的儿童比例亦显著高于2010年前剂量方案。
  • 2010剂量建议前后肝毒性总体无显著差异,但2010剂量后若干亚组肝毒性显著增加。
  • 研究间存在显著异质性;无研究处于高偏倚风险。

关键数值与推荐

  • 任何不良事件合并比例:WHO 2010剂量26%(95%CI 18%-34%)vs 2010年前剂量8%(95%CI 4%-15%)。
  • 严重不良事件比例:WHO 2010剂量显著高于2010年前剂量。
  • 肝毒性:2010剂量前后总体无显著差异,但2010剂量后若干亚组显著增加。

局限性

  • 研究结论受观察性试验发表偏倚的限制。
  • 研究间存在显著异质性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In 2010, the World Health Organization (WHO) increased the recommended doses of first-line tuberculosis (TB) drugs for children. In this systematic review, we aimed to determine the proportion of children who developed adverse events (AEs) on first-line TB treatment and determine whether a change in toxicity was observed with WHO 2010 dosing. METHODS: We searched MEDLINE, Embase, Scopus, Cochrane Central Register of Controlled Trials, WHO Global Index Medicus, and ClinicalTrials.gov for studies that reported AEs for children and adolescents aged ≤19 years with TB disease receiving first-line medications. A meta-analysis of proportions was performed to generate pooled proportions of AEs. The protocol was registered with the International Prospective Register of Systematic Reviews. RESULTS: Of forty studies comprising 5021 participants, 682 (13.6%) participants experienced 712 AEs; 60 (1.2%) participants experienced a change in therapy due to AEs. The proportion of children with any AE was significantly higher with WHO 2010 dosing (26%; 95% confidence interval [CI], 18%-34%) compared with pre-WHO 2010 dosing (8%, 95% CI, 4%-15%), as was the proportion of children who developed severe AEs. There was no significant difference in hepatotoxicity before and after 2010 dosing recommendations; however, significant increases in hepatotoxicity were seen in several subgroups with 2010 dosing. There was substantial heterogeneity between studies; none were at high risk of bias. CONCLUSIONS: Higher-dose regimens in children were associated with increased AEs, raising caution for further dose increases and necessitating additional study of treatment tolerability. These findings are limited by publication bias in observational trials.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Prodanuk M, Silverberg SL, Piché-Renaud PP, et al. Adverse Events of First-Line Therapy for Pediatric Tuberculosis: A Systematic Review and Meta-Analysis. Clin Infect Dis. 2026. PMID: 40127187. doi:10.1093/cid/ciaf152

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。